ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY24 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) issued an update on its FY24 earnings guidance on Friday morning. The company provided EPS guidance of $4.90-5.05 for the period, compared to the consensus EPS estimate of $4.72. The company issued revenue guidance of $594-602 million, compared to the consensus revenue estimate of $590.33 million. ANI Pharmaceuticals also updated its FY 2024 guidance to 4.900-5.050 EPS.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ANIP shares. Raymond James raised their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 18th. StockNews.com cut shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research note on Tuesday, October 22nd. HC Wainwright reaffirmed a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Finally, Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an "overweight" rating and a $68.00 target price for the company. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $77.33.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP traded up $3.77 during midday trading on Friday, reaching $62.15. The stock had a trading volume of 219,128 shares, compared to its average volume of 215,081. The stock has a market capitalization of $1.31 billion, a P/E ratio of 53.02 and a beta of 0.71. ANI Pharmaceuticals has a 1-year low of $48.20 and a 1-year high of $70.81. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. The firm's fifty day simple moving average is $58.70 and its 200-day simple moving average is $61.58.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. During the same quarter in the prior year, the company earned $1.06 EPS. The firm's revenue for the quarter was up 18.5% compared to the same quarter last year. On average, equities research analysts forecast that ANI Pharmaceuticals will post 3.5 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.